Eli Lilly: Necitumumab Improves Overall Survival In NSCLC Phase III Trial

(RTTNews) - Eli Lilly and Company (LLY) reported that the results from the Phase III trial in first-line squamous non-small cell lung cancer, or NSCLC, showed that Necitumumab Improved overall survival. In the Phase III SQUIRE trial, patients with stage IV metastatic squamous NSCLC showed a statistically significant improvement in overall survival with a median survival of 11.5 months when receiving necitumumab in combination with gemcitabine and cisplatin as a first-line treatment, as compared to 9.9 months for those treated with chemotherapy alone. Consistent efficacy results were observed across endpoints and subgroups.

Necitumumab is a recombinant human IgG1 monoclonal antibody designed to target the human epidermal growth factor receptor 1. With the new findings, Lilly anticipates a regulatory submission of necitumumab before the end of 2014.